Resource Library

Whitepapers

Mitigating early development risks with Samsung Biologics DEVELOPICK™ platform


Early identification of promising drug candidates is critical for safe and efficient development. In our latest whitepaper, Heonchang Lim, Director of Formulation Development, explains how we leverage our proprietary DEVELOPICK™ platform to streamline the discovery process, enhancing the likelihood of successful drug commercialization. 




Early identification of promising drug candidates is critical for safe and efficient development. In our latest whitepaper, Heonchang Lim, Director of Formulation Development, explains how we leverage our proprietary DEVELOPICK™ platform to streamline the discovery process, enhancing the likelihood of successful drug commercialization. 




SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION